BridgeMD
Comparison of low versus intermediate intravenous dexamethasone doses on rebound pain after ambulatory open foot surgery under popliteal sciatic nerve block: a double-blind clinical trial.
EU CTIS ID: 2025-523356-31-01
What this study is testing
To compare the incidence of rebound pain following outpatient open foot surgery under popliteal sciatic nerve block between patients receiving low versus intermediate prophylactic intravenous doses of dexamethasone.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients, ASA physical status I–III, scheduled for elective outpatient open orthopedic foot surgery performed under popliteal sciatic nerve block.
You likely can't join if
- Patients under 18 years of age.
- Patients with ASA physical status greater than III.
- Surgery not performed under regional anesthesia or cases with regional anesthesia failure.
- Patients with Type 1 diabetes mellitus.
- Patients undergoing treatment for chronic pain.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.